Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Author Correction: Targeting cardiac fibrosis with engineered T cells.

Aghajanian H, Kimura T, Rurik JG, Hancock AS, Leibowitz MS, Li L, Scholler J, Monslow J, Lo A, Han W, Wang T, Bedi K, Morley MP, Saldana RAL, Bolar NA, McDaid K, Assenmacher CA, Smith CL, Wirth D, June CH, Margulies KB, Jain R, Puré E, Albelda SM, Epstein JA.

Nature. 2019 Nov 14. doi: 10.1038/s41586-019-1761-7. [Epub ahead of print]

PMID:
31723271
2.

Targeting cardiac fibrosis with engineered T cells.

Aghajanian H, Kimura T, Rurik JG, Hancock AS, Leibowitz MS, Li L, Scholler J, Monslow J, Lo A, Han W, Wang T, Bedi K, Morley MP, Linares Saldana RA, Bolar NA, McDaid K, Assenmacher CA, Smith CL, Wirth D, June CH, Margulies KB, Jain R, Puré E, Albelda SM, Epstein JA.

Nature. 2019 Sep;573(7774):430-433. doi: 10.1038/s41586-019-1546-z. Epub 2019 Sep 11. Erratum in: Nature. 2019 Nov 14;:.

PMID:
31511695
3.

Motion artifact removal and signal enhancement to achieve in vivo dynamic full field OCT.

Scholler J.

Opt Express. 2019 Jul 8;27(14):19562-19572. doi: 10.1364/OE.27.019562.

PMID:
31503714
4.

Probing dynamic processes in the eye at multiple spatial and temporal scales with multimodal full field OCT.

Scholler J, Mazlin V, Thouvenin O, Groux K, Xiao P, Sahel JA, Fink M, Boccara C, Grieve K.

Biomed Opt Express. 2019 Jan 22;10(2):731-746. doi: 10.1364/BOE.10.000731. eCollection 2019 Feb 1.

5.

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.

Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I, Nazimuddin F, Bhoj VG, Orlando EJ, Fry TJ, Bitter H, Maude SL, Levine BL, Nobles CL, Bushman FD, Young RM, Scholler J, Gill SI, June CH, Grupp SA, Lacey SF, Melenhorst JJ.

Nat Med. 2018 Oct;24(10):1499-1503. doi: 10.1038/s41591-018-0201-9. Epub 2018 Oct 1.

6.

Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells.

Ghassemi S, Nunez-Cruz S, O'Connor RS, Fraietta JA, Patel PR, Scholler J, Barrett DM, Lundh SM, Davis MM, Bedoya F, Zhang C, Leferovich J, Lacey SF, Levine BL, Grupp SA, June CH, Melenhorst JJ, Milone MC.

Cancer Immunol Res. 2018 Sep;6(9):1100-1109. doi: 10.1158/2326-6066.CIR-17-0405. Epub 2018 Jul 20.

7.

Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.

Watanabe K, Luo Y, Da T, Guedan S, Ruella M, Scholler J, Keith B, Young RM, Engels B, Sorsa S, Siurala M, Havunen R, Tähtinen S, Hemminki A, June CH.

JCI Insight. 2018 Apr 5;3(7). pii: 99573. doi: 10.1172/jci.insight.99573. eCollection 2018 Apr 5.

8.

Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation.

Guedan S, Posey AD Jr, Shaw C, Wing A, Da T, Patel PR, McGettigan SE, Casado-Medrano V, Kawalekar OU, Uribe-Herranz M, Song D, Melenhorst JJ, Lacey SF, Scholler J, Keith B, Young RM, June CH.

JCI Insight. 2018 Jan 11;3(1). pii: 96976. doi: 10.1172/jci.insight.96976. eCollection 2018 Jan 11.

9.

Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18.

Hu B, Ren J, Luo Y, Keith B, Young RM, Scholler J, Zhao Y, June CH.

Cell Rep. 2017 Sep 26;20(13):3025-3033. doi: 10.1016/j.celrep.2017.09.002.

10.

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.

Ruella M, Barrett DM, Kenderian SS, Shestova O, Hofmann TJ, Perazzelli J, Klichinsky M, Aikawa V, Nazimuddin F, Kozlowski M, Scholler J, Lacey SF, Melenhorst JJ, Morrissette JJ, Christian DA, Hunter CA, Kalos M, Porter DL, June CH, Grupp SA, Gill S.

J Clin Invest. 2016 Oct 3;126(10):3814-3826. doi: 10.1172/JCI87366. Epub 2016 Aug 29.

11.

Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma.

Posey AD Jr, Schwab RD, Boesteanu AC, Steentoft C, Mandel U, Engels B, Stone JD, Madsen TD, Schreiber K, Haines KM, Cogdill AP, Chen TJ, Song D, Scholler J, Kranz DM, Feldman MD, Young R, Keith B, Schreiber H, Clausen H, Johnson LA, June CH.

Immunity. 2016 Jun 21;44(6):1444-54. doi: 10.1016/j.immuni.2016.05.014.

12.

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells.

Kawalekar OU, O' Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD Jr, Patel PR, Guedan S, Scholler J, Keith B, Snyder NW, Blair IA, Milone MC, June CH.

Immunity. 2016 Mar 15;44(3):712. doi: 10.1016/j.immuni.2016.02.023. Epub 2016 Mar 15. No abstract available.

13.

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells.

Kawalekar OU, O'Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD Jr, Patel PR, Guedan S, Scholler J, Keith B, Snyder NW, Blair IA, Milone MC, June CH.

Immunity. 2016 Feb 16;44(2):380-90. doi: 10.1016/j.immuni.2016.01.021. Erratum in: Immunity. 2016 Mar 15;44(3):712. Snyder, Nathaniel [corrected to Snyder, Nathaniel W]; Blair, Ian [corrected to Blair, Ian A]. Erratum in: Immunity. 2016 Mar 15;44(3):712.

14.

Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells.

Lo A, Wang LS, Scholler J, Monslow J, Avery D, Newick K, O'Brien S, Evans RA, Bajor DJ, Clendenin C, Durham AC, Buza EL, Vonderheide RH, June CH, Albelda SM, Puré E.

Cancer Res. 2015 Jul 15;75(14):2800-2810. doi: 10.1158/0008-5472.CAN-14-3041. Epub 2015 May 15.

15.

CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.

Kenderian SS, Ruella M, Shestova O, Klichinsky M, Aikawa V, Morrissette JJ, Scholler J, Song D, Porter DL, Carroll M, June CH, Gill S.

Leukemia. 2015 Aug;29(8):1637-47. doi: 10.1038/leu.2015.52. Epub 2015 Feb 27.

16.

Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma.

Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, Nace AK, Dentchev T, Thekkat P, Loew A, Boesteanu AC, Cogdill AP, Chen T, Fraietta JA, Kloss CC, Posey AD Jr, Engels B, Singh R, Ezell T, Idamakanti N, Ramones MH, Li N, Zhou L, Plesa G, Seykora JT, Okada H, June CH, Brogdon JL, Maus MV.

Sci Transl Med. 2015 Feb 18;7(275):275ra22. doi: 10.1126/scitranslmed.aaa4963.

17.

Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells.

Frigault MJ, Lee J, Basil MC, Carpenito C, Motohashi S, Scholler J, Kawalekar OU, Guedan S, McGettigan SE, Posey AD Jr, Ang S, Cooper LJ, Platt JM, Johnson FB, Paulos CM, Zhao Y, Kalos M, Milone MC, June CH.

Cancer Immunol Res. 2015 Apr;3(4):356-67. doi: 10.1158/2326-6066.CIR-14-0186. Epub 2015 Jan 19.

18.

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.

Guedan S, Chen X, Madar A, Carpenito C, McGettigan SE, Frigault MJ, Lee J, Posey AD Jr, Scholler J, Scholler N, Bonneau R, June CH.

Blood. 2014 Aug 14;124(7):1070-80. doi: 10.1182/blood-2013-10-535245. Epub 2014 Jul 1.

19.

Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.

Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, Kapoor V, Scholler J, Puré E, Milone MC, June CH, Riley JL, Wherry EJ, Albelda SM.

Clin Cancer Res. 2014 Aug 15;20(16):4262-73. doi: 10.1158/1078-0432.CCR-13-2627. Epub 2014 Jun 11.

20.

Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.

Wang LC, Lo A, Scholler J, Sun J, Majumdar RS, Kapoor V, Antzis M, Cotner CE, Johnson LA, Durham AC, Solomides CC, June CH, Puré E, Albelda SM.

Cancer Immunol Res. 2014 Feb;2(2):154-66. doi: 10.1158/2326-6066.CIR-13-0027. Epub 2013 Nov 12.

21.

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.

Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, Carroll M, Danet-Desnoyers G, Scholler J, Grupp SA, June CH, Kalos M.

Blood. 2014 Apr 10;123(15):2343-54. doi: 10.1182/blood-2013-09-529537. Epub 2014 Mar 4. Erratum in: Blood. 2016 Nov 24;128(21):2585.

22.

Enhanced function of redirected human T cells expressing linker for activation of T cells that is resistant to ubiquitylation.

Kunii N, Zhao Y, Jiang S, Liu X, Scholler J, Balagopalan L, Samelson LE, Milone MC, June CH.

Hum Gene Ther. 2013 Jan;24(1):27-37. doi: 10.1089/hum.2012.130. Epub 2012 Nov 6.

23.

Evidence that the density of self peptide-MHC ligands regulates T-cell receptor signaling.

Anikeeva N, Gakamsky D, Schøller J, Sykulev Y.

PLoS One. 2012;7(8):e41466. doi: 10.1371/journal.pone.0041466. Epub 2012 Aug 3.

24.

Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells.

Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, Vogel AN, Kalos M, Riley JL, Deeks SG, Mitsuyasu RT, Bernstein WB, Aronson NE, Levine BL, Bushman FD, June CH.

Sci Transl Med. 2012 May 2;4(132):132ra53. doi: 10.1126/scitranslmed.3003761.

25.

The role of innate APOBEC3G and adaptive AID immune responses in HLA-HIV/SIV immunized SHIV infected macaques.

Wang Y, Whittall T, Rahman D, Bunnik EM, Vaughan R, Schøller J, Bergmeier LA, Montefiori D, Singh M, Schuitemaker H, Lehner T.

PLoS One. 2012;7(4):e34433. doi: 10.1371/journal.pone.0034433. Epub 2012 Apr 13.

26.

Immunization with recombinant macaque major histocompatibility complex class I and II and human immunodeficiency virus gp140 inhibits simian-human immunodeficiency virus infection in macaques.

Yang GB, Wang Y, Babaahmady K, Schøller J, Rahman D, Bunnik E, Spallek R, Zong CM, Duan JZ, Qin C, Jiang H, Singh M, Vaughan R, Bergmeier LA, Schuitemaker H, Shao Y, Lehner T.

J Gen Virol. 2012 Jul;93(Pt 7):1506-18. doi: 10.1099/vir.0.041061-0. Epub 2012 Apr 4.

PMID:
22492918
27.

Breakthrough invasive mould infections in patients treated with caspofungin.

Pang KA, Godet C, Fekkar A, Scholler J, Nivoix Y, Letscher-Bru V, Massias L, Kauffmann-Lacroix C, Elsendoorn A, Uzunov M, Datry A, Herbrecht R.

J Infect. 2012 Apr;64(4):424-9. doi: 10.1016/j.jinf.2011.12.015. Epub 2011 Dec 29.

PMID:
22227384
28.

Ventricular bigeminy associated with voriconazole, methadone and esomeprazole.

Scholler J, Nivoix Y, Herbrecht R, Kemmel V, Levêque D.

Int J Clin Pharm. 2011 Dec;33(6):905-8. doi: 10.1007/s11096-011-9581-3. Epub 2011 Nov 23.

PMID:
22108788
29.

In situ detection of HY-specific T cells in acute graft-versus-host disease-affected male skin after sex-mismatched stem cell transplantation.

Kim YH, Faaij CM, van Halteren AG, Schrama E, de Jong TA, Schøller J, Egeler RM, Pavel S, Vyth-Dreese FA, van Tol MJ, Goulmy E, Spierings E.

Biol Blood Marrow Transplant. 2012 Mar;18(3):381-7. doi: 10.1016/j.bbmt.2011.10.038. Epub 2011 Nov 4.

30.

Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques.

Mörner A, Jansson M, Bunnik EM, Schøller J, Vaughan R, Wang Y, Montefiori DC, Otting N, Bontrop R, Bergmeier LA, Singh M, Wyatt RT, Schuitemaker H, Biberfeld G, Thorstensson R, Lehner T.

J Virol. 2011 Jul;85(13):6442-52. doi: 10.1128/JVI.00129-11. Epub 2011 Apr 13.

31.

Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.

Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, Albelda SM, June CH.

Cancer Res. 2010 Nov 15;70(22):9053-61. doi: 10.1158/0008-5472.CAN-10-2880. Epub 2010 Oct 5.

32.

A recombinant human HLA-class I antigen linked to dextran elicits innate and adaptive immune responses.

Schøller J, Singh M, Bergmeier L, Brunstedt K, Wang Y, Whittall T, Rahman D, Pido-Lopez J, Lehner T.

J Immunol Methods. 2010 Aug 31;360(1-2):1-9. doi: 10.1016/j.jim.2010.05.008. Epub 2010 Jun 10.

PMID:
20542039
33.

Externalization of the leaderless cytokine IL-1F6 occurs in response to lipopolysaccharide/ATP activation of transduced bone marrow macrophages.

Martin U, Scholler J, Gurgel J, Renshaw B, Sims JE, Gabel CA.

J Immunol. 2009 Sep 15;183(6):4021-30. doi: 10.4049/jimmunol.0803301. Epub 2009 Aug 28.

34.

Genetic engineering of T cells for adoptive immunotherapy.

Varela-Rohena A, Carpenito C, Perez EE, Richardson M, Parry RV, Milone M, Scholler J, Hao X, Mexas A, Carroll RG, June CH, Riley JL.

Immunol Res. 2008;42(1-3):166-81. doi: 10.1007/s12026-008-8057-6. Review.

35.

Nectin-like protein 2 defines a subset of T-cell zone dendritic cells and is a ligand for class-I-restricted T-cell-associated molecule.

Galibert L, Diemer GS, Liu Z, Johnson RS, Smith JL, Walzer T, Comeau MR, Rauch CT, Wolfson MF, Sorensen RA, Van der Vuurst de Vries AR, Branstetter DG, Koelling RM, Scholler J, Fanslow WC, Baum PR, Derry JM, Yan W.

J Biol Chem. 2005 Jun 10;280(23):21955-64. Epub 2005 Mar 21.

36.
37.

Mitogenic properties of a bispecific single-chain Fv-Ig fusion generated from CD2-specific mAb to distinct epitopes.

Connelly RJ, Hayden MS, Scholler JK, Tsu TT, Dupont B, Ledbetter JA, Kanner SB.

Int Immunol. 1998 Dec;10(12):1863-72.

PMID:
9885907
38.

LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile.

Skeiky YA, Kennedy M, Kaufman D, Borges MM, Guderian JA, Scholler JK, Ovendale PJ, Picha KS, Morrissey PJ, Grabstein KH, Campos-Neto A, Reed SG.

J Immunol. 1998 Dec 1;161(11):6171-9.

39.

Detection of fetal congenital heart disease in a low-risk population.

Hafner E, Scholler J, Schuchter K, Sterniste W, Philipp K.

Prenat Diagn. 1998 Aug;18(8):808-15.

PMID:
9742568
40.

[Effects of progesterone on proliferation and differentiation of fetal rat calvarial osteoblasts in vitro].

Chen L, Schøller J, Foged NT.

Zhonghua Fu Chan Ke Za Zhi. 1997 Sep;32(9):538-40. Chinese.

PMID:
9639754
41.

[Relation between common allelic variation in a cross-sectional longitudinal population study. Vitamin D receptor locus, bone mineral density and postmenopausal bone loss].

Jørgensen HL, Schøller J, Sand JC, Bjuring M, Hassager C, Christiansen C.

Ugeskr Laeger. 1998 Jan 26;160(5):648-53. Danish.

PMID:
9470473
42.

Functional characterization of the human biglycan 5'-flanking DNA and binding of the transcription factor c-Krox.

Heegaard AM, Gehron Robey P, Vogel W, Just W, Widom RL, Schøller J, Fisher LW, Young MF.

J Bone Miner Res. 1997 Dec;12(12):2050-60.

44.

Prenatal diagnosis of facial malformations.

Hafner E, Sterniste W, Scholler J, Schuchter K, Philipp K.

Prenat Diagn. 1997 Jan;17(1):51-8.

PMID:
9021829
46.
47.

Relationship of common allelic variation at the vitamin D receptor locus to bone mineral density and bone turnover.

Jørgensen HL, Schøller J, Sand JC, Bjuring M, Hassager C, Christiansen C.

Br J Obstet Gynaecol. 1996 May;103 Suppl 13:28-30; discussion 30-1. No abstract available.

PMID:
8624339
48.

ALP induction by beta-glycerophosphate during the non-mineralization phase in vitro.

Chen L, Schøller J, Foged NT.

J Tongji Med Univ. 1996;16(1):20-4.

PMID:
8758739
49.

Synthesis and evaluation of nuclear targeting peptide-antisense oligodeoxynucleotide conjugates.

Reed MW, Fraga D, Schwartz DE, Scholler J, Hinrichsen RD.

Bioconjug Chem. 1995 Jan-Feb;6(1):101-8.

PMID:
7711095
50.

Analysis of T cell receptor alpha beta variability in lymphocytes infiltrating melanoma primary tumours and metastatic lesions.

Schøller J, thor Straten P, Birck A, Siim E, Dahlström K, Drzewiecki KT, Zeuthen J.

Cancer Immunol Immunother. 1994 Oct;39(4):239-48.

PMID:
7954526

Supplemental Content

Loading ...
Support Center